FogPharma Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$112.6M
Industry:Biotech
Founded:N/A
Lead Investor(s):6 Dimensions Capital
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • FogPharma's estimated annual revenue is currently $10.7M per year.
  • FogPharma received $66.0M in venture funding in May 2018.
  • FogPharma's estimated revenue per employee is $155,000
  • FogPharma's total funding is $112.6M.

Employee Data

  • FogPharma has 69 Employees.
  • FogPharma grew their employee count by 23% last year.
  • FogPharma currently has 12 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Ohana Bioscienc...
$8.7M5660%N/A
Tango Therapeut...
$12.9M8338%N/A
Compass Therape...
$16.4M10614%N/A
Cell Signaling ...
$89.4M577N/AN/A
Momenta Pharmac...
N/A220N/AN/A
Emulate
$15.3M99-17%N/A
ArQule
N/A94N/AN/A
Hamilton Storag...
$17.2M1119%N/A
Alnylam Pharmac...
$74.9M127731%N/A
Transgenomic
N/A47N/AN/A
Missing a competitor? Contribute!?
Submit

FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered undruggable. The company's cell-penetrating miniproteins (CPMPs) combine the targeting power of protein therapeutics with the cell-penetrating ability of small molecules. This unique combination of targeting features enables CPMP's to access and engage proteins that have long been known to play a major role in causing serious human diseases, but have been frustratingly beyond the reach of therapeutic intervention. We are a vibrant and driven group of scientists and science lovers, with a strong entrepreneurial spirit, and deeply committed to our mission of adding years to life and life to years through the creation of transformative new medicines.

keywords:N/A

69

Number of Employees

$10.7M

Revenue (est)

12

Current Jobs

23%

Employee Growth %

$112.6M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
Martin TremblayExecutive Director, ChemistryEmail Available
Ivan JewettPrincipal ScientistEmail Available
Yaguang SiAssociate Director, BiologyEmail Available
Howard YoungVice President FinanceEmail Available
Kerry MarasaHR Business Partner
Ty ThomsonSenior Principal Scientist, Computational BiologyEmail Available
James MadsenPrincipal ScientistEmail Available
Zhang Yue-MeiSenior Director
Diana ChaiAssociate Director, BiologyEmail Available
Thomas BrutonPrincipal Research Associate, ChemistryEmail Available

FogPharma News

09/08/2019 - A new era for Alewife business park: life sciences

CAMBRIDGE — For nearly 20 years, Robert Schlager has been working on turning the old Alewife campus of renowned consulting firm Arthur ...

05/06/2019 - FogPharma beefs up R&D team with new CSO, discovery head

Howard Stern and Peter Fekkes join FogPharma as the biotech advances a beta-catenin inhibitor program for multiple cancers. (Pixabay).

06/12/2019 - Cambridge Discovery Park Building 400-500 Will be New ...

“We are thrilled that FogPharma has chosen to remain at CDP and expand in Building 400-500,” said Mike Wilcox, SVP, Director of Leasing at ...

FogPharma Funding

DateAmountRoundLead InvestorsReference
2018-05-17$66.0MB6 Dimensions CapitalArticle